Clinical Trial Update: A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing Capecitabine Rapid Disintegrating Tablets (RDT) to the commercial Xeloda formulation in patients with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer

Drugs mentioned

• Capecitabine Rapid Disintegrating Tablet (RDT) (capecitabine)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer, Colorectal Cancer | Phase 1 | Status: COMPLETED